Over the last two decades the outcomes of patients with amyloidosis have substantially improved with timely diagnosis, the use of chemotherapeutic agents and improved patient selection for autologous stem cell transplantation (ASCT); however, for patients who are diagnosed at later stages or who are ineligible for ASCT the prognosis is poorer. Recently, the introduction of daratumumab has shown promising results for patients with both newly diagnosed and relapsed/refractory amyloidosis and there have been a number of Phase II/III trials aiming to help guide treatment decision-making and improve patient outcomes.
In today’s podcast, Angela Dispenzieri, MD, of the Mayo Clinic, Rochester, MN, gives an overview of key updates in the treatment landscape of amyloidosis, as presented at the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
Recent advances in amyloidosis treatment
ASH 2021: a deep dive into ALL immunotherapy
ASH 2021: what did ASH 2021 mean for MDS?
ASH 2021: novel developments in MPNs
ASH 2021: evaluating the impact of screening for multiple myeloma precursor diseases
ASH 2021: the future of cell therapies in lymphoma
ASH 2021: highlights in CLL clinical trials
ASH 2021: updates in FLT3-mutated AML
The Lymphoma Sessions: post-ASH 2021
COSTEM: maintenance therapies for FLT3+ AML
COSTEM: the role of alloHSCT in ALL
IACH 2021: CAR-T in clinical practice
Unmet needs and recent updates in CML
IMW 2021: treatment-free intervals in multiple myeloma
Highlights from iwCLL 2021
IMW 2021: MRD in myeloma
CAR-T vs bispecifics: replacing ASCT in myeloma
EHA 2021: antibody therapies for NHL
EHA 2021: updates on novel agents for AML
Create your
podcast in
minutes
It is Free
Good Mood Revolution
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
Precision Medicine Forum Podcast
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive